Autologous haematopoietic stem/progenitor cell therapy (Sangamo Therapeutics/Bioverativ)

N/A

Report date: 2024/10/24 20:00:07

Base Information

Drug NameAutologous haematopoietic stem/progenitor cell therapy (Sangamo Therapeutics/Bioverativ)
Drug Alias NameZFN-Bcl11aBIVV-003SB BCLmR HSPCSAR-445136
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCell replacementsGene silencingHemoglobins stimulants +[4] 
TargetsHemoglobinsB-cell lymphoma/leukemia 11A
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiSangamo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A